FDA approves second GSK quadrivalent flu vax; Merck pulls Zilmax; Report: Eylea moves past Lucentis;

@FiercePharma: Trending online: Which are pharma's top 4 innovators? Hint: It's not the big guys. More | Follow @FiercePharma

@EricPFierce: FDA wants help figuring out how to stop addicts from getting to the APIs in opioid painkillers. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: The latest in India vs. Big Pharma IP developments: Roche won't pursue Herceptin patents in India. Article | Follow @CarlyHFierce

> The U.K.'s BioIndustry Association (BIA) has lambasted the country's drug pricing plans, saying it could make the country a pharma innovation backwater. Story

> The FDA has approved FluLaval Quadrivalent, a second quadrivalent influenza vaccine from GlaxoSmithKline ($GSK). Release

> Merck ($MRK) said today it is temporarily halting sales of the animal supplement Zilmax, a week after Tyson Foods said it wouldn't buy cattle that had been fed the growth hormone. Announcement

> The FDA is now requiring that labels and guides on all fluoroquinolone antibacterial drugs be updated to better describe the serious and permanent nerve damage they can cause. Notice

> InnoPharma has launched acamprosate calcium in the U.S., the generic version of Forest Laboratories' ($FRX) Campral. Item 

> GlaxoSmithKline's Tyverb has been cleared in the EU for use in combination with Roche's ($RHHBY) Herceptin in patients with HER2-positive, hormone receptor-negative breast cancer. Story

> Canada has approved ThromboGenics' Jetrea for the treatment of symptomatic vitreomacular adhesion (VMA). Release

Medical Device News

@FierceMedDev: UPDATED: Bard ordered to pay $2M in vaginal mesh trial defeat. News | Follow @FierceMedDev

@DamianFierce: A global cybersecurity outfit is lending a hand to the medical device industry. Article | Follow @DamianFierce

@MarkHFierce: Heathrow Airport have been warned that female terrorists might strike with breast implant explosives. Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: St. Jude nets FDA approval for low-radiation ablation catheters. Article | Follow @MichaelGFierce

> China targets medical device misuse. Item

> Coloplast feels weight of rival's vaginal mesh legal woes. Story

> Gene By Gene joins Ambry to fight Myriad's Dx 'monopoly.' Report

Biotech News

@FierceBiotech: We're looking for the fiercest women in biotech for our 2013 report. Editor's note | Nomination form | Follow @FierceBiotech

@JohnCFierce: MannKind rewarded for positive Afrezza data with $40M financing. Report | Follow @JohnCFierce

@RyanMFierce: Scientists found a causal link between a tooth cavity bacterium and colon cancer in mice, potential drug target. More from TheScientist | Follow @RyanMFierce

@EmilyMFierce: SeattleBioMed wins $16M NIH grant for tuberculosis research. ICYMI yesterday from FierceBiotechResearch.com | Follow @EmilyMFierce

> Shkreli's biotech Retrophin zeroes in on $25M financing with 'major' pharma deal looming. Article

> Epizyme picks up FDA orphan nod for lead cancer drug as going public pays off. News

> Ophthotech eyes $85M IPO to fund PhIII for drug to prevent blindness. Report

And Finally... A report from BioTrends found that Eylea's patient share now stands at 26% of surveyed doctors' wet age-related macular degeneration patients, compared with 21% for Lucentis, suggesting that in two years Eylea has overtaken the first-to-market drug. Story

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.